Albany Molecular Research Accounts Payable

Albany Molecular Research (AMRI) currently reports a accounts payable of $120M as of June 2017. That compares with $72M in the prior-year period — up 61.3% year over year. Use the charts on this page to explore Albany Molecular Research's accounts payable history and peer comparisons.

Albany Molecular Research's accounts payable increased from $72M to $120M — a 61.3% year-over-year increase (period ending June 2017). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Albany Molecular Research reported $120M in accounts payable as of June 2017. That compares with $72M in the prior-year period — up 61.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $120M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Albany Molecular Research, and consider following AMRI for alerts when major investors trade the stock.